Operating income |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2025 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Revenue [abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Operating income | Operating income Operating income is composed as below:
Research tax credit (“CIR”) The Group carries out research and development projects. As such, it has benefited from a research tax credit for the six-month periods ended June 30, 2024 and 2025 for an amount of €2,665 thousand and €2,017 thousand, respectively. Subsidies Subsidies primarily relate to the Bpifrance RNP-VIR and CARENA conditional advances, the repayments of which were partly waived by Bpifrance in June 2024, for €1,872 thousand and €2,251 thousand respectively (see Note 3.1).
|